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Within 1 procedure, tissue-engineered, living heart valves (TEHVs), fabricated from 
biodegradable scaffolds seeded with autologous bone marrow–derived mononuclear cells 
(Fig. 1A), were integrated into self-expanding nitinol stents (20 mm × 30 mm) and 
transapically delivered into the descending aorta (n = 2) (distal to the brachiocephalic trunk) 
and the brachiocephalic trunk (n = 1) of sheep (Fig. 1A). Native valve incompetence was 
created by applying the Hufnagel procedure (1) before implantation (Fig. 1A). After 
successful deployment (Figs. 1B and 1C), valve function and optimal positioning were 
confirmed using fluoroscopy (Fig. 1B, Online Video 1), computed tomography (CT) (Figs. 1D 
and 1E, Online Video 2), and echocardiography (Figs. 1F to 1M, Online Videos 3A, 3B, and 
3C). The crimping time of the TEHVs was 15 ± 2 min. The overall duration of the procedure, 
from the preparation of cells to the successful delivery, was 2 h. Post-mortem analysis 
displayed fully intact TEHVs and, in particular, well-defined leaflets showing coaptation. 
There were no signs of leaflet rupture, microstructure damage, or thrombus formation 
detectable. 
So far, successful TEHV implantations have only been reported for low-pressure systems 
such as in the pulmonary position (2), and clinical trials have been initiated. This is the first 
report demonstrating the feasibility of the minimally invasive, catheter-assisted implantation 
of TEHV into the systemic circulation with adequate valvular functionality in an acute study 
based on an easily accessible, clinically relevant cell source (3) and minimally invasive 
techniques for both cell harvest and delivery (2) within 1 procedure. Such autologous and 
living heart valves may hold potential to overcome the limitations of the currently used 
bioprosthetic valves inherently prone to calcification and progressive dysfunctional 
degeneration. This may broaden the future clinical application of transcatheter valves beyond 
elderly high-risk patients. 
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 Figure 1: Tissue-Engineered Heart Valves 
(A) Tissue-engineered heart valves (TEHVs) (inset) were transapically delivered into the descending 
aorta (distal to the brachiocephalic trunk) and into the brachiocephalic trunk of adult sheep after 
creating native valve insufficiency by applying the Hufnagel procedure. (B) Contrast angiography 
displayed optimal positioning and normal function of the TEHV. (C) Post-mortem analysis confirmed 
positioning in the descending aorta distal to the brachiocephalic trunk. (D and E) Three-dimensional 
(3D) computed tomography reconstruction of the adult sheep heart (D and E showing anterior view, 
inset showing posterior view) with the self-expanding nitinol stent positioned in the descending aorta 
(‡) distal to the brachiocephalic trunk (*). (F to M) Transesophageal echocardiography (TEE) in the 2-
dimensional (2D); (G and H), 2D color (I), and 3D (J to M) modes displayed the TEHV in the 
descending aorta (‡) above the native valve (*). In particular, the TEE analysis showed well-defined 
leaflets showing sufficient coaptation. There were no signs of pressure damage, leaflet rupture, or 
thrombus formation detectable. Also See Online Videos 1, 2, 3A, 3B, and 3C. 
 
